The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes

The Role of Aldosterone in Diabetes Related Vascular Disease, a New Therapeutic Target?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03017703

Enrollment

Registered

2017-01-11

Start date

2016-12-01

Completion date

2019-12-15

Last updated

2021-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Insulin Resistance

Keywords

Endothelial dysfunction, Insulin resistance, Type 2 diabetes, Mineralocorticoid blocker

Brief summary

The importance of Aldosterone for endothelial function and Insulin resistance observed within patients with type 2 diabetes

Interventions

DRUGEplerenone

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed diabetic \< 5 Yrs. * BMI \< 32 kg/m2 * Non-smoking * Blood pressure \< 140/90 mmHg (treatment with maximum of two antihypertensive drugs)

Exclusion criteria

* Insulin treatment * Hypertension (\>140/90 mmHg) * Sequelae to diabetes * Smoking * Known chronic diseases * Pregnancy or birth within 3 month * Alcohol misuse

Design outcomes

Primary

Measure	Time frame	Description
Vascular function	8 weeks	Femoral arterial blood flow in response to femoral arterially infused ACh
Insulin sensitivity measured by a insulin clamp	8 weeks	Glucose infusion rate during euglycaemic-hyperinsulinaemic clamp

Secondary

Measure	Time frame	Description
Vascular function	8 weeks	Microperfusion performed on blood vessels in vitro obtained from muscle biopsies

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026